WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) [...]
WEP Group Holdings Limited (WEP), a specialist CRO focused on delivering lifesaving drugs to patients that have an unmet clinical need, is expanding its capabilities by making a strategic investment in Wren Healthcare Limited [...]
WEP Clinical (WEP), the specialist pharmaceutical services company, has partnered with Mylan N.V. (Mylan), a global pharmaceutical company, to launch a Named Patient Access Program (NPAP) for a new chemical entity used to treat [...]
